Integrated Use of In Vitro and In Vivo Information for Comprehensive Prediction of Drug Interactions Due to Inhibition of Multiple CYP Isoenzymes
S Hozuki, H Yoshioka, S Asano, M Nakamura… - Clinical …, 2023 - Springer
Background Mechanistic static pharmacokinetic (MSPK) models are simple, have fewer data
requirements, and have broader applicability; however, they cannot use in vitro information …
requirements, and have broader applicability; however, they cannot use in vitro information …
Quantitative Prediction of CYP3A4‐and CYP3A5‐mediated drug interactions
Y Guo, A Lucksiri, GL Dickinson… - Clinical …, 2020 - Wiley Online Library
We verified a physiologically‐based pharmacokinetic (PBPK) model to predict cytochrome
P450 3A4/5‐mediated drug‐drug interactions (DDIs). A midazolam (MDZ)–ketoconazole …
P450 3A4/5‐mediated drug‐drug interactions (DDIs). A midazolam (MDZ)–ketoconazole …
Use of a physiologically based pharmacokinetic model for quantitative prediction of drug–drug interactions via CYP3A4 and estimation of the intestinal availability of …
Y Mano, Y Sugiyama, K Ito - Journal of pharmaceutical sciences, 2015 - Elsevier
The purpose of this study was to predict the drug–drug interactions (DDIs) via CYP3A4 by
estimating the extent of hepatic CYP3A4 inhibition based on a physiologically based …
estimating the extent of hepatic CYP3A4 inhibition based on a physiologically based …
Prediction of drug‐drug interactions using physiologically‐based pharmacokinetic models of CYP450 modulators included in Simcyp software
N Marsousi, JA Desmeules, S Rudaz… - … & drug disposition, 2018 - Wiley Online Library
In recent years, physiologically based PharmacoKinetic (PBPK) modeling has received
growing interest as a useful tool for the assessment of drug pharmacokinetics. It has been …
growing interest as a useful tool for the assessment of drug pharmacokinetics. It has been …
A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug–drug …
H Guo, C Liu, J Li, M Zhang, M Hu, P Xu, L Liu… - Journal of …, 2013 - Elsevier
ABSTRACT Cytochrome P450 (CYP) 3A induction-mediated drug–drug interaction (DDI) is
one of the major concerns in drug development and clinical practice. The aim of the present …
one of the major concerns in drug development and clinical practice. The aim of the present …
Quantitative prediction of drug interactions caused by CYP1A2 inhibitors and inducers
L Gabriel, M Tod, S Goutelle - Clinical pharmacokinetics, 2016 - Springer
Background A simple method to predict drug–drug interactions mediated by cytochrome
P450 enzymes (CYPs) on the basis of in vivo data has been previously applied for several …
P450 enzymes (CYPs) on the basis of in vivo data has been previously applied for several …
Prediction of in vivo drug–drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant
HS Brown, K Ito, A Galetin… - British journal of clinical …, 2005 - Wiley Online Library
Aims Success of the quantitative prediction of drug–drug interactions via inhibition of CYP‐
mediated metabolism from the inhibitor concentration at the enzyme active site ([I]) and the …
mediated metabolism from the inhibitor concentration at the enzyme active site ([I]) and the …
Prediction of In Vivo Drug-Drug Interactions from In Vitro Data: Factors Affecting Prototypic Drug-Drug Interactions Involving CYP2C9, CYP2D6 and CYP3A4
HS Brown, A Galetin, D Hallifax, JB Houston - Clinical pharmacokinetics, 2006 - Springer
Background Quantitative predictions of in vivo drug-drug interactions (DDIs) resulting from
metabolic inhibition are commonly made based upon the inhibitor concentration at the …
metabolic inhibition are commonly made based upon the inhibitor concentration at the …
Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based …
YH Wang - Drug Metabolism and Disposition, 2010 - ASPET
Accurate prediction of the extent of mechanism-based CYP3A inhibition is critical in
determining the timing of clinical drug interaction studies in drug development. To evaluate …
determining the timing of clinical drug interaction studies in drug development. To evaluate …
Static and dynamic projections of drug-drug interactions caused by cytochrome P450 3A time-dependent inhibitors measured in human liver microsomes and …
E Tseng, H Eng, J Lin, MA Cerny, DA Tess… - Drug Metabolism and …, 2021 - ASPET
Cytochrome P450 3A (CYP3A) is a frequent target for time-dependent inhibition (TDI) that
can give rise to drug-drug interactions (DDI). Yet many drugs that exhibit in vitro TDI for …
can give rise to drug-drug interactions (DDI). Yet many drugs that exhibit in vitro TDI for …
相关搜索
- drug interactions quantitative prediction
- comprehensive prediction cyp isoenzymes
- drug interactions cyp isoenzymes
- integrated use cyp isoenzymes
- integrated use comprehensive prediction
- drug interactions integrated use
- drug interactions cyp1a2 inhibitors
- drug interactions pk sim
- drug interactions intestinal availability
- drug interactions cyp3a4 substrates
- drug interactions parallel pathways
- drug interactions comprehensive prediction